Page last updated: 2024-11-05

thalidomide and Lymphangiectasis

thalidomide has been researched along with Lymphangiectasis in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Lymphangiectasis: A transient dilatation of the lymphatic vessels.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arellano-Rodrigo, E1

Other Studies

1 other study available for thalidomide and Lymphangiectasis

ArticleYear
Case 23-2010: Unusual paraprotein effects in MGUS--treat or not?
    The New England journal of medicine, 2010, 11-04, Volume: 363, Issue:19

    Topics: Antineoplastic Agents; Humans; Kidney Diseases; Lenalidomide; Lymphangiectasis; Lymphangioma, Cystic

2010